Presenting & Exhibiting Companies
Larta Programs
Lartas "Global Bridge" Companies
Lartas Tech-Transfer Program - University Spinout
NIH-Funded "CAP" Companies
Specially Selected Companies From Lartas Network
Bionext Produtos Biotecnologicos Ltda.
Bionext, based in Brazil, has specialized in producing Microbial Cellulose (MC), a versatile biomaterial with broad applications in industries as diverse as food, electronics, and paper products. Our first product is a highly-effective wound-dressing material which improves the healing process for burns and for chronic and acute wounds. Our other important offerings involve MC membranes for internal use and biostents coated with biosynthetic cellulose, which is 100% biocompatible and is effective in controlling restenosis following coronary angioplasty.
FK-Biotecnologia S.A.
FK Biotecnologia is a Brazilian Fully Integrated Biotechnology Company (FIBCO) extended to clinical service with a diversified clinical stage pipeline of cancer therapeutic strategies. Also acting on great business opportunities in South America with global impact such as the Immunodiagnostics, Biosensors, Nanotechnology and Recombinant Protein Technology.
Genoa Biotecnologia S.A.
Genoa Biotechnology is a Brazil-based biotech company founded in 1999 whose core business is in the area of molecular genetics, and which occupies a place of pride in the development and deployment of DNA and dendritic cell therapeutic vaccines targeting tumor and viral diseases. Our initial work in therapeutic dendritic cell vaccines for metastatic renal cell carcinoma and melanoma showed considerable impact in cancer therapy in a trial involving 190 patients. We hold a worldwide license to LAMP (lysosome-associated membrane protein) technology for applications in HIV and cancer; LAMP was discovered and patented by Dr. Tom August, a distinguished professor in the field of pharmacology and immunology. Our work extends also to developing vaccines for epidemic-related diseases such as yellow fever, where we are studying replacing conventional vaccine made from inactive virus.
ImmunoVaccine
Immunovaccine Technologies Inc. (IVT) develops vaccines targeting infectious disease and therapeutic vaccines targeting cancer. We have developed a breakthrough vaccube delivery and enhancement system (VacciMax)a nd immunotope, an antigen discovery platfrom with a large selection of validated vaccine antigens. The combination of the right antigens and strong novel discovery will give IVT's product pipeline a distinct competitive advantage. We are positioned to be a key player in the development of premium vaccine products and to bring value to our partners' vaccine development, antigen and adjuvant programs.
Nuvector Pharmaceuticals Inc
Nuvector Pharmaceuticals Inc., a pharmaceutical company specializing in innovative polymeric technologies, acquired exclusive rights to POLYMERIC MICELLES, a drug delivery platform developed for i.v. oncology. Polymeric Micelles features outstanding characteristics to deliver poorly water-soluble drugs, resulting in safer and more efficacious treatments. In addition, the Company holds the exclusive rights to GLIADIN-BINDING POLYMERS, a means of treating orally subjects having Celiac disease, a gluten-induced disorder. This technology benefits from a major market opportunity with about 1% of population in North America afflicted with this chronic disease. Nuvector seeks private equity investors in order to translate these technologies into products.
Pacific Therapeutics Ltd.
Pacific Therapeutics Ltd. is a development stage Specialty Pharmaceutical Company, poised to begin clinical trials with its lead compound PTL-202 in Idiopathic Pulmonary Fibrosis (IPF). PTL-202 is a combination of already approved drugs with a well established safety profile. There are no approved or effective therapies for IPF and the median survival time from diagnosis is only 2.8 years. The company is focused on IPF because of its aggressive nature however PTL-202 is applicable to other fibrotic diseases like Scleroderma Associated Pulmonary Fibrosis, Lung Transplant Rejection, Liver Cirrhosis and others. Together these markets represent an opportunity in excess of $4.5 billion.
Photon Biomed Inc.
Photon Biomed builds on a breakthrough hyperspectral imaging technology
developed initially at Caltech by Photon etc's founder. Among the medical conditions that the technology can address, Aged related Macular Degeneration (AMD) was identified as the most promising market where Photon etc's technology was uniquely positioned to bring an early diagnostic tool to the medical professionals.
With our Hyperspectral Retinal Camera, early signs of AMD can be identify before any detectable damage is visible, thus avoiding loss of vision. This early diagnostic can save sight of millions of people thanks to drugs slowing down the progress of that otherwise incurable disease.
Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and distributes patented, super-pulsed laser and light-based technology systems used in a wide range of therapeutic clinical applications. The Theralase technology platform has been proven clinically effective in non-invasive pain management and clinical therapy, including hundreds of different neural muscular skeletal conditions such as sports injuries, repetitive strain injuries and arthritis. Theralase has patented technologies currently under research and development focused on two main areas: increased clinical efficacies in therapeutic treatment and the destruction of cancer, viruses, bacteria and fat cells through the light activation of specially designed photodynamic compounds. Visit www.theralase.com for more detailed information.
AbaStar MDx
AbaStar MDx is a molecular diagnostic company developing proprietary blood-based gene expression, molecular diagnostic tests for the accurate diagnosis of mental disorders and neurodegenerative diseases. For brain disorders, this breakthrough enables accurate diagnosis with laboratory tests for the first time. Resultant early detection, monitoring, disease progression and effective treatment of these diseases would eliminate years of patient suffering from misdiagnosis and trial and error treatments. Our focus diseases for products include schizophrenia (SZ), bipolar disorder (BD), depression, Alzheimer's and Parkinson's disease. Initial market entry will be tests which accurately diagnose and differentiate patients with SZ and BD from blood sample.
Active Life Technologies
Active Life Technologies (ALT) produces innovative medical devices and diagnostics based on never before available in vivo material property measurements. ALT's current product focus, the Bone Diagnostic Instrument (BDI), measures the intrinsic mechanical properties and physical fracture resistance of bone, in vivo. Measurements will provide doctors with new diagnostic information allowing for more complete and accurate fracture risk assessments. The BDI is portable, easy to operate and utilizes a cost effective razor-razor blade model. Osteoporosis thought leaders from around the world have used the BDI for laboratory and preliminary clinical research. The BDI is ready for more advanced clinical studies.
Aursos, Inc.
Aursos is an emerging biotechnology company leveraging the evolutionary advantages that the black bear has developed over millions of years to escape the debilitating effects of osteoporosis and other bone related diseases. Black bears have developed a means to build bone while inactive, while inactivity in humans generally results in osteoporosis. The 10 billion dollar osteoporosis market has a number of drugs that inhibit the loss of bone but only one replaces lost bone, Eli Lilly's Forteo®. Aursos lead product, Black Bear parathyroid hormone (BB-PTH1-34) is poised to take the treatment of osteoporosis beyond that of Forteo®. BB-PTH 1-34 not only builds bone strength but will likely enhance the overall activity of bone building cells in humans. The potential of offering a lower dose may result in an enhanced safety profile and greater compliance.
Calibrant Biosystems
Calibrant is pioneering the development of novel therapeutics for major unmet medical needs using its Gemini(TM) proteomic technology. Gemini allows the elucidation of disease-relevant pathways and protein networks from targeted cells captured from clinical tissue specimens. Our disruptive approach to proteomics enables comprehensive and quantitative protein profiling of isolated and homogeneous cell populations from both fresh and archival formalin-fixed tissues, allowing us to approach the full biology of disease pathogenesis with exquisite sensitivity. Our sample requirements are uniquely matched to microdissection methods including laser capture microdissection (LCM). The ability to extensively and reproducibly probe the proteome is coupled with an integrated bioinformatics suite enabling effective data mining within a biological context. Thus, Calibrant's approach provides unique benefits for drug discovery and development, as well as the identification of predictive (bio)markers for personalized medicine and companion diagnostics.
We are fully committed to the reality that a proteomics company must produce tangible value propositions and products moved to market - and cannot merely generate reams of data as a purposeless platform technology. Consequently, our company's initial pipeline - focused on the development of antibody drugs against ovarian, breast, and brain cancer - is already in validation stage and moving towards our initial IND. In tandem with our fund-raising, we are seeking additional strategic partners to further validate our technology and identify novel therapeutic targets in other major markets.
Centrose
Centrose is using its proprietary CarboConnect™ technology to make better drugs. With CarboConnect™, we can enhance almost any class of drug rapidly and at low cost. We intend to use CarboConnect™ to develop improved, proprietary versions of existing drugs with large markets and significant unmet medical need. To date, we have used CarboConnect™ to discover compounds with improved activity against cancer and infectious disease. We plan to work aggressively with strategic partners to leverage our technology and develop our pipeline of products to maximize the value of the company.
Colby Pharmaceutical
Colby is developing a new class of small molecule Oxidative Stress Modulator (OSM) therapeutic drugs that specifically target and therapeutically modulate pathologic changes resulting from cellular oxygen free radical damage in Prostate Cancer (PCa) and Benign Prostatic Hyperplasia (BPH). Colby’s lead drugs have unique mechanisms of action and target multiple Oxidative Stress (OS) generating hormonal, inflammatory and oxidase enzyme induced prostate disease pathways. The Company is clinically developing its lead drugs, CPC-100 and -200, for recurrent PCa following surgery and radiation, but prior to detection of metastasis.
Frost Biologic
Frost Biologic is a BYU spin-out addressing a large, unmet market need in oncology medicine for drugs that arrest the spread or metastasis of cancer.
The company is in early stage development with one lead compound.
i3Bio, LLC
i3Bio fills an unmet need in the clinical laboratory for quick, definitive diagnosis of disease-causing mycobacteria. i3Bio is seeking Series A equity or JV financing for FDA approval and to market its beta-tested, proprietary platform technology. The World Health Organization estimates that 1/3 of the world is latently infected with TB. Active drug resistant TB and other mycobacterial infections are rapidly increasing worldwide. Unlike current technologies, laboratories receive instant diagnosis via a web-accessible, curated database. To ensure continuous revenue growth, i3Bio's platform will be rapidly extended to the clinical market for differential molecular diagnosis of fungi and other medically-relevant microorganisms.
Kinexis Inc.
Kinexis is developing novel immunotherapeutics for the treatment and prophylaxis of neurodegenerative diseases such as Alzheimer's and Parkinson's Disease. Kinexis technology allows generation of specific antibodies that specifically target cytotoxic conformations of amyloid proteins such as the amyloid beta peptide responsible for pathology in Alzheimer's Disease. Kinexis has generated a vaccine candidate based on proprietary technology that prevents pathology in mouse models of Alzheimer's disease, and has identified monoclonal antibodies with specificity and affinity appropriate for development as passive immunotherapy for Alzheimer's disease.
Meditrina Pharmaceuticals
Meditrina is a clinical-stage specialty pharmaceutical company focused on developing and commercializing novel therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs. By repurposing marketed products, Meditrina's therapies have the potential to significantly improve how these conditions are treated. Meditrina's products are based on anastrozole, a marketed aromatase inhibitor (AI), repurposed stand-alone and in combination therapy for: (1) endometriosis; (2) uterine fibroids; (3) menorrhagia; (4) thinning of the endometrium pre-surgery; and (5) ectopic pregnancy. Meditrina will aggregate the required IP, conduct dose-ranging trials, and conduct the pivotal trials required for approval. Within 3-4 years, Meditrina will sell itself to a pharmaceutical company with late stage pipeline needs or commercialize its products through a specialty sales force. Meditrina is seeking to raise a $19-23 million Series A and total of $50 - $55 million in stages to submit up to three NDAs over the next three years.
MicroMRI, Inc.
MicroMRI is a medical device company focused on high-resolution Magnetic Resonance Imaging of bone trabecular microarchitecture and subsequent quantitative modeling of bone quality and bone strength. The FDA and other health organizations have recently changed the definition of osteoporosis as being “impaired bone strength”. MicroMRI is the first company to provide a clinical routine quantitative measure of bone strength and bone quality that addresses this new definition of osteoporosis. MicroMRI's product can be used in the diagnosis of osteoporosis and the assessment of treatment effects during osteoporosis therapy. With the ageing population, osteoporosis will become an even more important health issue.
Multimeric Biotherapeutics
Members of the Tumor Necrosis Factor (TNF) Superfamily of ligands, normally produced as trimers, have now been produced as highly active multimers (i.e., many trimers). In published studies, we showed that CD40 ligand (CD40L), when produced as a soluble “multimeric” molecule using our patented technology (“UltraCD40L”), is highly active as a vaccine adjuvant and tumor immunotherapy agent in preclinical models. A Phase 1 human trial of a therapeutic cancer vaccine is the next step.
Quantum Logic Devices
QLD's technology platform is built on nanoscale transistors that are sensitive to the binding reactions of single molecules. Essentially, the current flow through each transistor is switched by the reaction of a single biomolecular probe on its surface. QLD has proven single molecule detection of DNA and antibody (immunoassay) examples. By fabricating these devices in large arrays, extended dynamic range and sensitivity are possible. Prototypes are being evaluated now, and first products will be available in 2008.
Tissue Genetics Inc.
Tissue Genetics Inc. is a molecular diagnostics company with unique technology for improving the care of patients with genetic diseases. Our proprietary biomarkers identify patients with hereditary diseases helping to determine their optimum course of care. The first products based on our patented technology will address significant market needs in the diagnosis and treatment of breast, ovarian and colorectal cancers. These products will establish a new paradigm in screening for these significant diseases and will disrupt an established market, saving lives, time and money. Tissue Genetics diagnostic tests are faster, easier, more accurate and less expensive than any other technology option. These products represent an annual market opportunity of over $1 Billion.
Acoustic MedSystems, Inc.
Acoustic MedSystems, Inc. (AMS) focuses on the development of minimally invasive interventional methods for treatment, treatment guidance, and delivery monitoring. These are predominately real-time methods for imaging, image processing and therapy delivery guidance. Included are its proprietary ACOUSTXTM technology (Applicators with Controllable Output of Ultrasound for Selective Treatment) for minimally invasive targeted thermal ablation of tumors and other soft-tissue diseases and its spatially-registered image guidance methodologies for treatment delivery and monitoring. The ACOUSTX technology can provide significant benefits and improvements over traditional surgical procedures, as well as over other minimally invasive thermal technologies, and has treatment potential for a wide range of soft-tissues (malignant and benign tumors, other soft tissue disorders) including breast, liver, uterus, prostate, brain, lung, bladder, and colo-rectal diseases. Additionally, the technology can be effective for the treatment of prostate BPH, uterine fibroids, and stress urinary incontinence. The other core technologies of the company are in image registration and real-time intraoperative treatment guidance and monitoring.
Advanced Circulatory Systems, Inc.
Advanced Circulatory Systems is focused on developing and commercializing a sudden cardiac arrest resuscitation system. The platform for this system is a combination of proprietary technologies developed by Advanced Circulatory Systems to increase blood flow during CPR and survival rates for cardiac arrest victims. The goal is to create a cost-effective treatment system through an optimized integration of multiple cardiac arrest-related technologies that will significantly improve cardiac arrest survival rates.
AfaSci, Inc.
AfaSci, Inc. currently develops a wireless, non-invasive rodent homecage monitoring system for in vivo high-throughput screening (HTS) of drug efficacy and safety, and for behavioral phenotyping of transgenic and knockout mice, through collaborations with Pennsylvania State University, Pennsylvania, The George Washington University, Washington, D.C.), and research institutions (SRI International, CA). We provide products and services in these areas.
In the future direction, we will explore contract services on in vivo drug screening and potentially new drug discovery via commercial contracts, collaborations and/or partner with both biotech or pharmaceuticals.
AJ Medical Devices, Inc
AJ Medical Devices develops monitoring systems for the high-risk patient that are based on small sensors implanted under the skin that communicate externally via wireless. The first product, CardioAlarm, has an implanted sensor that records a patient's EKG, automatically detects an abnormal heart rhythm, and transmits an alarm and EKG recording to a 24/7 patient monitoring service, without the encumbrance of electrodes on the skin and wires tethering the patient to a recorder. AJ Medical is seeking capital to complete FDA requirements, begin manufacture and marketing of CardioAlarm, and develop the next in a series of minimally invasive and wireless physiologic monitors.
Akaza Research
Akaza Research has developed OpenClinica, the leading open source clinical trial data capture and management software platform. Akaza brings Open Source Software (OSS) into the mainstream of the clinical research enterprise by making robust, flexible, standards-based systems accessible for private and public research. Akaza Research provides OpenClinica support, training, and consulting services to its customers worldwide.
Allied Innovative Systems, LLC
Allied Innovative Systems (ALLIS) is a research and development company engaged in the development of new technologies in the field of biochemical and biomedical assays and reagents. In particular, we have developed several techniques that increase the sensitivity of enzyme-mediated fundamental analytical assays. This work was supported by NIH SBIR grants. Now, we are in the process of negotiations regarding the commercialization of these technologies with a market leader in biomedical diagnostics. Several novel biochemical assays, such as development of new homogeneous analytical assays based on generation of singlet oxygen and detection of fluorescence polarization, were also developed by ALLIS.
Applied Scientific Research
Applied Scientific Research (ASR) develops state-of-the-art user-friendly design and analysis software to simulate complex fluid dynamical processes of interest to government and industrial clients in the bioengineering and medical products sectors, as well as the environmental, animation, aerospace, automotive, maritime, and process engineering fields. ASR's flagship simulation software, ?-Flow, is exceptionally simple to use; reduces user's time to set up a simulation by at least an order of magnitude, from traditional weeks~months to just hours~days; and predicts complex unsteady flow physics with very high accuracy and optimal CPU utilization. At present, ASR has NIH support to develop a highly advanced "virtual test chamber" to predict blood flow about mechanical heart valves under physiologically realistic flow conditions. Other complementary NIH projects in the pipeline will support the development of modules for simulating particulate-laden flow, which will be used to model flow of platelets and red blood cells in plasma, as well as transport of drug aerosols or airborne pollutants through upper respiratory tracts.
Archimage, Inc.
Archimage is a twenty-four-year-old design studio and winner of over thirty international awards for architecture, television commercials, videogames, websites, and graphic design. The company is wrapping up development of two videogames targeted to preventing obesity and type II diabetes in children.
The rising incidence of type II diabetes has reached epidemic proportions, especially among children and young adults. Causes are linked to poor diet and lack of exercise. Diabetes, the leading cause of new blindness and kidney failure, is also the nation's sixth leading cause of death. The predicted societal and economic impacts are staggering.
Videogames are one of the fastest-growing businesses in the entertainment world. Research shows a majority of children and teenagers spend an hour a day playing videogames. The average age videogame player is 33 years old.
Archimage believes significant consumer markets exist for videogames that promote healthy lifestyles.
Atmospheric Glow Technologies, Inc.
Atmospheric Glow Technologies, Inc. (AGT) is a science and engineering company developing products based upon patented One Atmosphere Uniform Glow Discharge Plasma (OAUGDP®) technology. The company has assembled an experienced and diverse team of experienced officers and highly trained scientists and engineers committed to technology commercialization. AGT owns two patents and has exclusive rights to eight patents. AGT's technology uses radio-frequency electric power to generate plasma from air which in turn produces highly oxidative chemical species that can be used beneficially in several application areas. AGT's plasma doesn't require special gases or vacuum conditions so it costs less to operate than other plasma technologies. AGT has introduced two products and is working to commercialize other plasma products in the areas of biotechnology, medical device sterilization, air purification, and disinfection of food and other agricultural products.
BioFormatix, Inc.
BioFormatix is a research and development company specializing in software and devices for the biomedical market, and in challenging problems in data mining and modeling. Our product pipeline includes (1) diagnostic aid software for screening and detection of glaucoma using perimetry (visual field) data, (2) light-weight, highly portable, user-friendly perimeter for glaucoma screening, and (3) novel software package for analysis of molecular expression data and detection of differential expression. Other interests include computerized tools for management of diabetes mellitus and medical diagnostic aid software.
BioHesion Inc.
BioHesion has developed expertise in surface chemistry with an emphasis on derivatizing inert surfaces with biomolecules. We have produced a number of recombinant proteins and peptides which bind gold through high affinity peptide tags, while retaining their biological activity. Based on this, we have developed Goldbinder technology for application in BioSensor and Biomaterials markets. We have developed sensor applications for surface plasmon resonance and colloidal gold to support commercialization of the technology. We are also establishing proof of principle in animal models for Goldbinder technology to enable Biomaterials with robust surface coatings for imaging and drug delivery.
Bioptigen, Inc.
Bioptigen's pioneering in vivo optical imaging technology allows academic and life science researchers to see pathologies at their earliest stage with unprecedented detail and clarity, across a wide range of subject applications. This sophisticated OCT hardware and software system enables real-time non-invasive imaging of internal tissue microstructure at an unmatched level of precision and depth, and extends the application space to cover a wide range of human and animal subjects. These advances make it possible for researchers to open up new avenues of biological exploration and development, and to foster advances in disease detection and management.
BrightOutcome
BrightOutcome offers patient-centric solutions for home-based, coordinated management of chronic disease symptoms, helping patients to reduce suffering, improve daily functioning, and avoid unnecessary clinic/ER visits. Our products utilize latest patient-reported outcomes (PRO) research and e-health/telehealth technologies to conduct adaptive PRO assessments anywhere and anytime, and provide just-in-time individualized patient education content to empower patients to self-manage their symptoms. We collaborate with more than a dozen top-rated research and patient-care institutions in product development/validation under many competitive NIH SBIR grants/contracts. We also work closely with the PROMIS Network, an NIH Roadmap project, to promote the use of PRO into mainstream clinical practice.
Caring Technologies, Inc.
Caring Technologies, Inc. delivers a specialty web-based Personal Health Record (PHR) platform which is enhanced by its exclusive worldwide license to a proprietary data capture system called BI Capture™. By delivering these via its popular online autism communication network TalkAutismTM, the Company will revolutionize behavioral medicine treatment and research while providing enriched interaction between individuals with autism and professionals who can be anywhere in the world. Stemming from its traction in the autism category, CT will apply this platform to other pressing health conditions, where the company can leverage this unique hybrid of technology services to facilitate treatment for Alzheimer's, Parkinson's, Traumatic Brain Injury, Post Traumatic Stress Disorder, and other costly neurological, neuromuscular and broader chronic illness populations. Ultimately, CT's technology platform will appeal to the more general health marketplace directly or via sublicense.
CellASIC Corporation
CellASIC develops and commercializes microfluidic products for cell culture screening. Our technology enables life science researchers to recreate physiologically relevant conditions for cell-based studies with improved data quality, higher throughput, and reduced cost. We are currently developing the PErfusion ARray Liver (PEARL) toxicity screening platform. This consists of single-use microfluidic plates and a modular system for primary hepatocyte loading. Once loaded, the plates are "self-contained" and compatible with standard lab automation equipment. CellASIC was founded from the UC Berkeley Bioengineering Department in 2005, and commercialized its first products for microfluidic cell culture in 2007.
CFD Research Corporation
CFD Research Corporation (CFDRC) is a technology focused small business, specializing in the development of innovative products and services, across three major markets (Aerospace, Life Sciences and Materials). The Biomedical division is focused on the development of application-specific microfluidic biochips, including the Synthetic Microvascular Network (SMN), for diverse medical and biotech applications. CFDRC is located in Huntsville AL and has over 90 employees, most of them with advanced degrees. We are currently exploring several means of bringing SMN to market - a dedicated start-up, product development in current organization with sales/distribution partners or technology licensing.
Creatv MicroTech, Inc.
Creatv MicroTech, Inc. is developing sensitive biodetection platforms. Creatv's vision is to become a major supplier of diagnostic tests, analytical tools and reagents for the water, food, environmental, pharmaceutical and medical industries. Creatv achieves innovations through both independent and joint research & development with universities and research laboratories. Creatv also performs development in microfabrication. Creatv manufactures advanced x-ray anti-scatter grids and nuclear collimators to improve medical imaging and received R&D 100 Award in 2006 for these products.
Danya International, Inc.
Danya International, Inc., designs and implements breakthrough solutions through the creative use of multimedia communications, information technology, and evidence based research. Our mission is to have a social impact on public health and education. As a social impact company, Danya dedicates its resources and talent toward the impact on six social goals: reduce tobacco, alcohol, and other drug use and addiction; improve the quality of comprehensive early childhood education; enhance child and family health; promote mental health education; reduce rates of new HIV infections and other infectious diseases; and promote diversity and inclusion in everything we do.
The Multi-Problem Youth (MPY) screening and assessment system is an innovative user friendly tool designed to be rapidly administered to adolescents by primary care and mental health providers. This product offers an engaging use of technology which is unique in the screening and assessment marketplace.
DEKK-TEC, Inc
DEKK-TEC is a R&D company that has been designing and developing new anticancer drugs and delivery systems since 1983. We have the ability to design, synthesize, test and prepare agents for pre-clinical studies and then finalize their IND applications. DEKK-TEC also has extensive experience in designing and managing Phase I/II clinical trials. Two of our drugs are in Phase II trials (licensed to Tigris Pharmaceuticals and Ziopharm Oncology) and a third - DM-CHOC-PEN is ready to enter Phase 1 trials. To date, we have taken three drugs through IND submission and into clinical trials. We also have prepared and submitted two 510K applications for devices and assisted with their licensing and commercialization.
Our present objective is to continue to create and develop clinical stage investment/partnership opportunities based on our current novel cancer therapeutic agent DM-CHOC-PEN, as well as for additional compounds in preclinical development at DEKK-TEC.
Dimera Incorporated
Dimera Incorporated is a grant-funded biotech company developing formulations to address angina pectoris and myocardial ischemia in women. Dimera was founded by Dr R Kent Hermsmeyer and investment partners in Portland, Oregon in 1997, based on observations that primate coronary reactivity was suppressed to normal physiological range by low-dose replacement of progesterone, but not medroxyprogesterone acetate. These independently verified studies demonstrate that considerable improvement of coronary function can result from progesterone replacement even with low doses, thus offering a well-tolerated, logical, effective option to current therapies.
EduMedia, Inc.
EduMedia is an e-health company specializing in the prevention of disease and the promotion of wellness. We create tailored educational programs for high-risk populations that maintain the health status of users and produce cost-savings for employers. Our current areas of focus are skin cancer, breast cancer, diabetes, low back pain, and depression. Evidence-based behavioral interventions, effective educational strategies, and engaging multimedia content are used to deliver high impact solutions with low unit costs. We seek strategic partnerships with providers of corporate wellness services, forward-looking managed care organizations, high-volume insurers and payers, and established e-health companies.
eHuman (Brown & Herbranson Imaging)
eHuman, Inc., and parent company Brown & Herbranson Imaging, are leading providers of 3-D interactive anatomical software applications, services and human datasets for dental, medical and consumer markets. Our core products, already in use within 50% of U.S.-based dental schools, bring the latest volumetric computing, interactive visualization and learning solutions to the spatially complex field of dentistry. Based upon the educational and economic value of our initial products, we are developing the industry's first Web-based, haptics-enabled surgical simulator and digital curriculum platform, enabling a first-in-class, 21st-century dental pedagogy. Additionally, working with partners including the Stanford School of Medicine, Smithsonian and Max-Planck Institute, our eHuman.com subsidiary is developing the most comprehensive, research-class anatomical imaging, reference and digital learning library for broader health care applications.
Energetiq Technology, Inc.
Energetiq is a developer and manufacturer of advanced short wavelength light sources that enable nano-scale structures and products. Used in complex scientific and engineering applications, Energetiq's light products are based on new technology that generates high brightness and high power light in the 1nm to 400nm range. Energetiq originally developed this technology and associated products for the semiconductor industry, and is now introducing them into the life sciences community. Potential applications include soft x-ray microscopy, deep UV-VIS spectroscopy, circular dichroism spectroscopy, UV microscopy and other analytical applications.
Engineering and Scientific Research Associates
Engineering and Scientific Research Associates, Inc. (ESRA), is a Maryland based R&D Company developing non-invasive medical devices (respiratory diagnostic devices) for use in pulmonary function testing (lung function tests, etc.) APD is our first diagnostic device that is nearly completed and will soon be manufactured and marketed.
First Light Biosciences
First Light Biosciences is an early stage Massachusetts company developing novel automated medical diagnostics products with an unequalled combination of sensitivity, accuracy, cost-effectiveness, and ease-of-use. Based on its proprietary MultiPath™ imaging technology that counts molecules and cells without magnification, the company's products address the rapidly growing $18B automated immunoassay diagnostics market. High volume, high-margin consumable sales drive the company's revenue model. First Light is currently developing the first system for large scale testing and triage after a major bioterrorism attack or infectious disease outbreak. This unique system addresses a critical gap in public health preparedness that could lead to thousands of needless deaths due to inefficient targeting of medical resources in a crisis. Product development is currently being funded by a $4.1M NIH grant. The product pipeline targets high volume routine hospital testing, and includes a powerful new test for detecting healthcare acquired infections.
Genego
GeneGo is a leading provider of data mining & analysis solutions in systems biology. Our tools and databases help to capture and define the underlying biology behind different types of high-throughput experimental data and understand the effects of small molecule drug compounds in human tissues. We provide systems biology solutions for a full range of applications in life science research and drug development, from pre-clinical discovery and NCE applications to clinical trials, covering all aspects of biology and chemistry.
Genopsys
Genopsys offers proprietary technologies for the rapid optimization of novel protein products. Our methods enable unprecedented protein engineering capabilities that can radically alter protein structure including the insertion of large segments without compromising functionality. We also create counterintuitive mutations near enzymatic sites without disrupting catalytic activity. We have demonstrated this core, platform technology with a beta-lactamase bacterial enzyme, but our methods can potentially be used to format drug flexibility, tailor in vivo half-life, engineer novel binding affinities and improve the performance characteristics of a industrial, pharmaceutical and diagnostic proteins. Our methods can transform a single-function molecule into a nano-scale machine with multiple functions, and engineer selectivity into existing small-scale proteins thus integrating the advantages of antibodies with the benefits of small-molecule drugs. As our technologies are applicable to a wide variety of proteins, our platform promises to transform the way disease is detected, treated and managed in cancer, CNS disorders, and a litany of other illnesses.
Genopsys is a privately held company. We are currently seeking strategic alliances to make our technologies more available, and unlock the many therapeutic and diagnostic applications our methods enable.
HealthCare Interactive, Inc.
HealthCare Interactive, Inc. is a privately-held health media company based in Minneapolis, MN that is committed to developing the most innovative set of dementia-related training programs available on the market today. To accomplish this, HCI has developed comprehensive Web-based, DVD, and CD-ROM delivered educational programs for patients, caregivers, and professional health workers (doctors, nurses, aides, and individuals involved in the care of the elderly or demented). HCI's software programs are ground breaking, innovative, engaging, research-based, and research-validated. Each program has won wide acclaim from family members and professional caregivers alike. Our research partners include researchers from Alzheimer's Association, Duke University, Emory University, and the University of Minnesota.
Infinite Biomedical Technologies, LLC
Infinite Biomedical Technologies is developing neurodiagnostic monitoring technologies for timely and accurate brain assessment of patients in the ICU, ER and EMS environments. Our solutions provide clinically validated quantitative evaluation of EEG via advanced signal processing with portability and ease of use design. These products allow for rapid feedback where none was previously available (i.e. neurological status for the non-neurologist) and potential cost savings to providers. The company is targeting the following scenarios (brain injury in adult post-cardiac arrest or newborn birth, seizures in clinical settings or civilian/military chemical attacks) with plans to expand into other related application areas.
Infoscitex Corporation
IST is a research, development, and engineering firm providing technology solutions and services for defense, life science, and energy & environment customers. IST's scientists and engineers have an established record of developing technologies from concept to reality and delivering high-value solutions. Core focus areas and services include: Drug Enhancement & Delivery, Electromechanical Systems, Information Technology, Communications, Electronics, Material Processing, Medical Devices, Robotics, Sensors, Research, Development, Commercialization/Transition, Engineering, Systems Analysis/Design, Quality Assurance, Independent Test/Validation, Technology Support, Modeling/Simulation, Technology Assessment, Software Development, and Systems Integration. Infoscitex has 60 employees, and is headquartered in Waltham, MA
INFOTECH Soft, Inc.
INFOTECH Soft, Inc. creates innovative software solutions for healthcare and the life sciences. We continuously expand the state of the art in information technology and computer engineering to create tools that enhance the productivity of health professionals and institutions. Our products focus on the collection, processing and management of clinical trial data, and on the integration of information from diverse and disparate sources into a comprehensive, unified semantic environment.
Innovative Biologics, Inc.
Innovative Biologics, Inc. is an anti-infective drug company targeting microbes producing pore-forming toxins. Our lead candidate targets Methicillin-resistant Staphylococcus aureus (MRSA), where we block a-toxin, a key virulence factor of MRSA. Our compound has demonstrated in vivo success and we shall complete PK feasibility studies mid-2008, demonstrating IB-201 is a viable drug candidate. Our approach to blocking pore-forming toxins has broad applicability in Hepatitis C, Group A Strep, C. difficile and Influenza. IBI has been funded with $1.8 million in NIH grants and $200,000 in investment funding from CIT BioLife Fund and Johnson & Johnson. With $2 million in funding we have two preclinical candidates, a patent portfolio and science at the leading edge of bacterial infection.
Intrinsic Bioprobes Inc
Intrinsic Bioprobes Inc. has developed proprietary tools and methods enabling high-throughput protein analysis and characterization toward biomarker discovery and validation. Mass Spectrometric Immunoassay (MSIA™ - Tips) are affinity pipettes that selectively isolate proteins from biological media. Bioreactive Probes (BRP™) are specialized 96 well plates that modify proteins in a way that is ideal for mass spec analysis. Incorporated into the MASSAY® System and using robotic processes, our platform is capable of analyzing up to 2,500 samples per day. These integrated resources radically reduce the cycle time and cost associated with research programs, drug development, diagnostics and clinical trials evaluations.
Investigen
Investigen is an R&D company dedicated to improve upon existing technologies and develop new Molecular Diagnostic tools. Investigen is developing a proprietary smartDNA™; Molecular Diagnostic platform. While smartDNA can be used in laboratories, its simplicity should make it uniquely able to serve in diagnostic tests that can be used away from a central lab (in peripheral labs, at the POC or at the point of sample collection (POS)).
InvoTek, Inc.
InvoTek specializes in technology-based solutions that meet the needs of people with disabilities. InvoTek and our partners have concentrated on developing new ways for people to access computers when standard access methods (mouse and keyboard) are impossible. We have demonstrated the feasibility of four new technologies, including: 1) A 3-D tracking system that enables a person to control the position of a computer cursor using head movement. 2) A very low cost eye-tracking system that enables people to control the position of a computer cursor using eye movement. 3) A dysarthric speech recognition system that, when used in conjunction with word prediction techniques, reduces the number of letters a user must enter by 70% when typing text into a computer. 4) A large-area, light-sensing surface that enabled InvoTek to design eye-safe laser systems for entering text into computers and controlling speech generating devices.
ISW Group, Inc.
ISW Group was founded in 2001 and is a privately held St. Louis-based company. ISW's mission is to research, develop, and market FDA-approved topical products designed to manage and treat acute and chronic inflammatory skin conditions. ISW has developed a patented technology platform that targets a therapeutically effective dose of drug to relevant dermal targets while minimizing systemic effects. ISW has completed FDA pre-clinical and clinical safety studies for its lead product for the management and treatment of Pseudofolliculitis barbae (PFB), a potentially debilitating dermatologic condition. Additionally, ISW's technology platform is expected to be useful for a variety of skin conditions including acne keloidalis, boils, dermatitis (eczema), rosacea, and burns.
Jambeyang Research
Jambeyang Research was founded in 2003 to develop innovative information systems to improve healthcare services. With in-depth understanding about the breast imaging services and extensive experience in IT management and software development, we have developed a state-of-the-art electronic medical record system for mammography and breast ultrasound, a highly regulated healthcare sector. This product provides streamlined appointment scheduling, patient history taking, report generation, patient follow-up, and MQSA support functions that will improve performance and patient satisfaction while reducing cost for breast imaging facilities. Unique user interfaces, lesion location computation, and multi-language features are our advantages over competing products.
Leo Lens Technology
Leo Lens Technology, founded in 2001, has innovated the next generation of specialty coatings for contact lenses to create additional market of more than billion dollars. Using enabling inkjet printing technology, we have developed contact lenses that provide an exact digital image of an iris with true colors on the lens for cosmetic application &/or antimicrobial coating for healthier eye &/or comfort enhancement for increased use. We provide multiple benefits to the consumer, optometrist and manufacturer. Our growing patent portfolio of more than 20 patents is comprehensive and global. We have FDA approval. We provide multiple benefits to the consumer, optometrist and manufacturer. Leo Lens Technology is looking for a strategic and financial partner for commercialization.
LightSpin Technologies, Inc.
LightSpin Technologies, Inc. develops the world's highest performance solid-state photon detectors, achieving single photon sensitivity, high quantum efficiency, wide dynamic range, large photosensitive area and low noise. LightSpin's photon detectors will supplant fragile, expensive, high voltage photomultiplier tubes with a low cost, low voltage, robust, solid-state solution. These photon detectors are critical components for a wide range of light starved applications, including biomedical instruments, chemical analysis instruments, and PET scanners.
Micron Optics, Inc.
Micron Optics Inc. (MOI) is a leading provider of advanced optical sensing technologies for Bio-medical, Industrial, and Defense/Security sectors. In the bio-medical field, MOI is developing high-speed swept-wavelength lasers for in-vivo, high-resolution optical coherence tomography imaging of diseased and cancerous tissue.
MicroSurfaces, Inc
MicroSurfaces, Inc. develops and markets cutting edge surface technologies to meet the needs of biosensor and high-through assay users in drug discovery and biomedical research. Technological superiority, combined with a keen understanding of customer needs, has allowed MicroSurfaces to become a leader and enabler of emerging high throughput techniques in proteomics, glycomics and nanomedicine. Target Markets are academics, research institutes and pharmaceutical companies worldwide.
Mimosa Acoustics, Inc.
Mimosa's main mission and interest is in research, development and manufacturing of preventive inner and middle ear diagnostics. Mimosa prefers to work with strategic partners in the hearing health care industry to market our technology. The technology developed by Mimosa for measuring wide-band acoustic ear-canal input impedance has important implications and applications in the audiological diagnostic and rehabilitative markets. Mimosa plans to develop each of those areas and will provide novel methods to improve the health care in the hearing related areas.
Molecular Design International, Inc.
Molecular Design International's (MDI) business model is to discover small molecule therapies and to out-license them to larger biopharmaceutical companies for continued development and commercialization. This approach allows MDI to maintain a highly cost-effective approach to creating innovative treatments for various conditions, while benefiting from the ultimate commercialization of those discoveries through milestone and royalty bearing agreements.
Since 1991 MDI has completed six licensing agreements with various biopharmaceutical development companies including Glaxo, Eli Lilly, and J&J. Much of MDI's success has been made possible through ten SBIR/STTR grants ranging from Phase 1 to Phase 3.
Nanotherapeutics, Inc.
Nanotherapeutics, Inc. is a specialty pharmaceutical company with one FDA-approved injectable biologic product (OrigenTM DBM, marketing partner Orthofix) and in-house GMP manufacturing. Nanotherapeutics is entering clinical trials with an orally-bioavailable abuse-deterrent particle dispersion of buprenorphine (NanoBUP) for opiate addiction and plans to pursue chronic pain as a second indication. NanoBUP would replace a $300M/year sublingual formulation that is difficult to administer and high absorption variability. The 8-year old company employs several platform technologies to manipulate and enhance the properties of drugs, has an experienced management team and a pipeline of clinical and pre-clinical pharmaceutical and biologic products.
Novaflux Technologies
Princeton Trade and Technology, Inc. d/b/a Novaflux Technologies is a Princeton, NJ-based, medical device and technology company founded in 1988 by Dr. Mohamed E. Labib. To date, the Company has received over $6.0 million from SBIR grants from various government agencies including the National Institutes of Health (NIH), contract research and development (R&D) projects, and licensing. These monies were used to develop the “two-phase flow” technology platform and hemodialyzer and endoescope reprocessors. The Company has 8 US patents on two-phase flow technology, methods, compositions, and devices.
Omicia, Inc.
Omicia is developing a genomics-based diagnostic test to evaluate patients' risk of cardiovascular disease. This test, based on a proprietary set of predictive biomarkers, allows doctors to more accurately stratify patients, avoiding more costly and dangerous diagnostic procedures. This diagnostic is currently undergoing clinical validation in collaboration with UC San Francisco. Omicia discovered the relevant biomarkers using its proprietary disease-gene identification system, which it expects will enable more accurate identification of networks of disease-relevant genes. Using this capability, Omicia plans to develop multiple genomic diagnostic tests, as well as sell data into the personalized genomics market.
Omneuron, Inc.
Omneuron is a life sciences technology company pioneering the use of functional brain imaging for therapeutic intervention. Omneuron is developing methods to translate the exciting progress made in functional MRI brain imaging during the past decade into clinical applications. The Omneuron research team works at a state of the art research facility, with the benefit of access to our own 3T MRI scanner, the support of six NIH grants, exciting technology, and fantastic collaborators. We are currently carrying out clinical trials using real-time functional MRI in two therapeutic areas.
Oxford Biomedical Research, Inc.
Oxford Biomedical Research (OBR), founded in 1984, develops and manufactures high quality biological reagents and assay kits for the life science research market, primarily for oxidative stress and chronic inflammation, two major factors known to be involved in the development of many diseases. OBR is launching a new company - Wellness Indicators, Inc. - to manufacture and market oxidative and inflammatory testing technology in formats suitable for routine assessment of an individual's wellness, and the impact of lifestyle, exercise, diet and nutraceutical supplements on one's health.
Perinatronics Medical Systems, Inc.
Perinatronics Medical Systems, Inc., is a small high-tech company involved in the hardware and software development of electronic medical instrumentation, including the fields of electrocardiography, fetal heart rate monitoring and magnetic resonance imaging.
Photon Migration Technologies
We are pioneering the development of a new economical, portable, and scalable assessment modality that can provide novel insights about integrated body function, early detection of disease states and actions of pharmaceutical agents. Central to this capability is the ability to explore, in real-time, the complex interactions between tissue and its blood supply. To capture this information we have designed a proprietary measurement and analysis platform that can be applied to tissue sizes that range from small animals to man (infants to adults) and equine populations. Our technology is economical, compact, portable and noninvasive.
PICS, Inc.
PICS, Inc. is a health technology company best known for its LifeSign® family of consumer products addressing tobacco cessation (QuitKey®), healthy diet and exercise (DietMate®) and insomnia (SleepKey®). LifeSign® has enjoyed worldwide market acceptance as evidenced by over 1.25 million units sold generating over 100 million dollars in sales. PICS is poised now to greatly save time and money for the research and clinical communities with the introduction of CERTAS®, a researcher - configurable fully integrated EDC system utilizing eDiaries, wireless technology and Interactive Voice Recognition. The uniqueness of CERTAS® will accelerate the design and management of clinical studies. PICS is seeking a partner with the marketing muscle to exploit the large potential for CERTAS® in the CRO and pharmaceutical industries.
Potomac Affinity Proteins, LLC
Potomac Affinity Proteins, a research and development company, has developed proprietary methods to engineer high-specificity, processing proteases. Potomac has already developed a protease/affinity tag technology for purifying proteins of scientific and pharmaceutical interest. This technology will benefit structural genomics efforts which rely on high-throughput, parallel processing of samples, large-scale purification of pharmaceutical proteins, and rapid production of vaccines in response to naturally-emergent (e.g., avian flu) and intentionally-introduced pathogens (e.g., bio-terrorism). Future development will focus on proteases for use in biosensors and therapeutics.
Powerscope Incorporated
Powerscope is active in two industry sectors, i.e. Medical Devices and Optical Instrumentation.
Key personnel of Powerscope have expertise in aerosol technology and optical diagnostics. The company is involved in the development and commercialization of drug delivery devices and innovative instrumentation based on its advanced technologies.
Target markets for Powerscope's technologies are
· Hospitals for drug delivery to patients;
· Research laboratories for drug delivery in pre-clinical animal research;
· Industrial quality control market for optical diagnostics.
Powerscope has established close working relationship with the pharmaceutical and medical faculty at the University of Minnesota. Powerscope's advisors have experience in launching hi-tech companies that have been very successful.
Powerscope has locally built a network of experts that enable development of advanced products, small-scale manufacturing, and initial sales and marketing efforts.
Precision Bioassay
Precision Bioassay is a small, growing statistical consulting and software development company specializing in statistical methods for biological assays of pharmaceutical proteins and vaccines. We offer comprehensive, best practice statistical bioassay services as well as statistical training and consulting services focused on non-clinical bioassay issues for pharmaceutical and biotechnology companies. Our customers are primarily developing protein, vaccine, cell and gene therapy products. We are working to transform bioassay by making it easy for industry laboratories to implement best practice in statistical methods for bioassay. Towards that end, we are developing a comprehensive software package, called Xymp™.
Prognosys Biosciences
Prognosys Biosciences is developing innovative assay technologies in the pharmacogenomics and chemical genomic space for life sciences research and development.
Our strategy is to:
1) Develop and make available novel assays for applications ranging from basic research to clinical diagnostics
2) Use them to discover and validate molecular markers that have prognostic value
3) Commercialize products and services that are transformative for life sciences applications
Protein Discovery, Inc.
Protein Discovery, Inc. (PDI) is a privately-held life sciences company providing proprietary sample preparation solutions for clinical mass spectrometry. The company is headquartered in Knoxville, TN and employees 12 individuals. PDI has developed three unique sample preparation platforms: (1) imaging mass spectrometry (IMS), (2) specialty reagents for protein research using mass spectrometry, and (3) its MALDIplex(TM) M5 Sample Prep Station. IMS is currently offered as a service and the reagents are sold as products. Both currently produce operational cash flow. MALDIplex is scheduled for product launch in Q1 2008.
Sanaria, Inc.
Sanaria Inc. is the only company in the World dedicated to the development and deployment of a vaccine against Plasmodium falciparum malaria and the vaccine under development is the only current approach which has a demonstrated efficacy in humans and the potential to prevent malaria in > 90% of recipients. Sanaria's PfSPZ vaccine comprises live radiation-attenuated P. falciparum parasites. We have now moved into a 23000 square foot facility which includes a cGMP plant for manufacturing vaccine and produced the first lot of cGMP product. Sanaria's mission is the development of PfSPZ vaccine for the Global Health market; however, there is a huge demand for the same vaccine among military personnel and travelers to malaria-endemic areas. This dual market/mission makes Sanaria a socially-focused for-profit enterprise.
SciTech Development, LLC
SciTech Development is a Detroit based oncology drug company that has developed a novel intravenous drug-delivery formulation of the drug fenretinide that achieves dosage levels shown to cause selective cancer cell death without producing toxic/allergic reactions. SciTech's proprietary fenretinide formulation has enormous potential for the successful treatment of several difficult to treat cancers including pancreatic, lung, and ovarian cancers and neuroblastoma. The product pipeline includes the delivery of other insoluble like drugs, combination therapies, and targeted drug delivery to specific organs. SciTech is looking for additional investments to bring its novel product formulation through Phase I/II Clinical Trials.
sComm
sComm, Inc develops, engineers, and manufactures the UbiDuo Face to Face Communicator. The UbiDuo enables a deaf/hard of hearing and a hearing individual to communicate with each other face to face without the need of an interpreter. The goal is to allow deaf, hard of hearing, and others with communication barriers to strike up a conversation with hearing people anywhere anytime such in professional or social communication situations. The UbiDuo changes the landscape for face to face communication. The development of the UbiDuo was funded by a grant from the National Institute on Deafness and Other Communication Disorders with the National Institute of Health. sComm was founded by father and son out of frustration when they both were trying to converse with each other over breakfast on Saturday morning 5 years ago.
SVision, LLC
Since 1999, SVision has been pioneering the use of machine learning technologies for flexible and accurate automatic image analysis applications. SVision's flagship product, SVCellTM, is the leading teachable image and data analysis software for advanced microscopy image analysis applications. Nikon is SVCell initial partner for biopharma markets. SVision is seeking partners to enter imaging based clinical diagnostic markets. SVision is an innovator with 30 issued and 18 pending U.S. patents. SVision staff has over 140 years experience of practical imaging solutions and a history of technical breakthroughs.
Tanglewood Research, Inc.
Tanglewood Research, Inc. has as its mission to translate behavioral technology into practical applications in the area of health promotion. The company focuses on the develop of products and services in three interdependent areas: effective programming to promote wellness and the prevention of risky behaviors, tools for conducting research and evaluation to assess the effectiveness of health and wellness interventions (particularly for adolescents), and the professional development of health promotion and prevention service providers.
TDA Research, Inc.
TDA Research is a privately held small business in Colorado that develops novel materials and process technologies for the health care, chemical, biochemical, and energy industries. TDA has developed an asymmetric hydrogenation process that can be used to make valuable chiral drugs and intermediates more efficiently and cheaper than traditional batch processes. Current chiral drug manufacturing is done in batch processes that require elaborate separation steps to recover expensive precious metal catalysts from the products. Our process efficiently separates the chiral catalyst from the product and the process can be operated in a batch or continuous mode. Compared to conventional processing, our separation process can cut down the number of process steps and can significantly reduce capital and operating costs.
TechniScan, Inc.
TechniScan Medical Systems (TMS) is a privately held medical device company engaged in the development and commercialization of a revolutionary ultrasound imaging system, UltraSound CTTM (WBUTM), to aid in the diagnosis of breast cancer. TMS' imaging system is designed to provide physicians with a new, non-invasive, diagnostic imaging tool that will provide detailed information about the anatomy (i.e. physical structures within the breast) and pathology (i.e. bulk tissue properties). The system is intended to be used as an adjunct to mammography to aid physicians in diagnosing breast cancer by helping to differentiate normal or benign from malignant tissue in the breast.
The Virtual Reality Medical Center
The Virtual Reality Medical Center, with clinics in San Diego, Los Angeles, and Palo Alto is a world leader in applying virtual reality technology in combination with physiological monitoring and feedback. VRMC software/hardware technology is used for:
*Evaluation and treatment of patients with anxiety disorders
*Distraction for patients with acute or chronic pain
*Treatment of returning veterans with posttraumatic stress disorder
*Cognitive rehabilitation of patients with traumatic brain injury Clinical studies, both published and in progress, show that this technology is safe, effective, and cost effective, because VR can speed the attainment of desired outcomes.
Transtimulation Research Inc.
Transtimulation Research Inc. is a startup company based in Oklahoma City. The mission of the company is to develop novel methods for the diagnosis and treatment of digestive disorders and obesity. Currently, the company has been working on electrical stimulator for the treatment of obesity. Particularly the company has a number filed patents on new methodologies for the treatment of obesity using electrical stimulation of the gut. In addition, the company is also working new methods of electrical stimulation for the treatment of diabetes and functional gastrointestinal disorders.
TSRL, Inc.
Therapeutic Systems Research Laboratories (TSRL), Inc. is a pharmaceutical research firm, specializing in oral drug delivery, drug transport and biopharmaceutical properties of drug delivery. We have developed a variety of formulations for improved oral drug delivery, including pulsatile drug release technology, the Programmable Oral Release Technology (PORT) Capsule, and water insoluble drug technology. TSRL, Inc. developed PK simulation software for the pharmaceutical and biotechnology industries. More recently we have focused on prodrug strategies as well as the development of a carrier technology, the Bile Acid Conjugate (BAC), which enable oral delivery of highly polar and/or charged drug candidates.
Urovalve, Inc.
Urovalve is an early stage company whose mission is to design, develop, and commercialize superior medical devices that address problems with urinary flow and control. Urinary retention can be caused by neuromuscular problems that impair the ability to relax the urinary sphincters or by physical obstructions to the urethra, and affects up to 6 million men. Urovalve's innovative intraurethral valved-catheter is designed to return control of bladder emptying to the user, therefore improving quality of life and reducing urinary tract infection risk. The commercialization of this Surinate® device will launch Urovalve into the urology segment of the medical device industry.
VPDiagnostics, Inc.
VPDiagnostics, Inc. develops software products that identify, analyze and visualize the dangerous vulnerable plaque responsible for most strokes. Leveraging patented technologies and collaboration with our university research partners, we have a unique product that employs MRI for imaging and analyzing atherosclerosis in vivo; and that has been undergone extensive pathological validation. Our product is the only one specialized in plaque characterization within the arterial wall with the carotid arteries as the initial area of application.
Our mission is to improve stroke prevention by providing a critical tool to better estimate the risks of most strokes. VPDiagnostics is achieving its goal through an experienced team, innovative technologies, application focused design, quality execution, and clinical and industrial partnership.
Ximerex, Inc.
Ximerex, Inc. proposes to satisfy a major unmet need in organ and tissue transplantation. Using the tools of hematopoietic stem cells, cell therapy, and xenotransplantation, the Company has developed proprietary technology to transplant tissues from pigs without the need for drugs to prevent rejection.
Hematopoietic stem cells from the patient are processed and grown within fetal pigs. The human T regulatory cells from the injected pig are later isolated and transferred back into the patient, conveying specific tolerance to the donor pig. Subsequently, pig tissue is transplanted into the patient. The technology is useful for type 1 diabetes, heart failure, etc.
XL Sci-Tech, Inc.
XL Sci-Tech develops and produces timed bioabsorbable radioactive devices for the treatment of soft tissue cancers. It has developed a protectable timed-bioabsorbable biomaterial platform along with a proprietary micro-fabrication process for radioactive materials. The first application is the creation of BetaSpheres®, which consists of timed-bioabsorbable Y-90 microspheres for treatment of inoperable hepatocellular carcinoma (HCC) and metastatic liver cancer. The application of timed-bioabsorbable delivery of Pd-103 for prostate cancer and other soft tissue cancers expands the scope of brachytherapy and makes timed-bioabsorbable matrix a true encapsulation and delivery platform for gamma emitters, as well as beta emitters. Timed-bioabsorbable brachytherapy seeds advance the state-of-the-art and offer critical new treatment options that are no possible with the current seed technologies.
Zylon Medical Devices
Zylon Medical Devices is a division of Zylon Corporation in New York. Core competency involves the development of innovative medical devices through the use novel polymeric materials and the application of advanced polymer processing methods. Zylon is presently focusing on developing a line of cardiac angioplasty balloon catheters which will have a significantly smaller crossing profile than all other catheters of equivalent size currently being marketed in the US or Internationally. These low profile catheters incorporate our patented “no-fold or low fold” angioplasty balloon design. These catheters can be used as pre-dilation devices and/or as low profile stent delivery platforms for direct stenting. They also have application in the treatment of chronic total occlusions (CTO).They are particularly suitable for use in countries where smaller coronary arteries are more common than in the US and Europe.
When it comes to coronary balloon catheters, “smaller is always better”.
AFrame Digital, Inc.
AFrame has developed a prototype non-intrusive wireless health monitoring and intelligent alerting system to support residents and patients and their caregivers in institutional, outpatient and home settings. The technology accepts real-time inputs from multiple wireless sensors, uses a scalable intelligent design, adaptive time-frequency statistical analysis techniques, cognitive learning/reasoning for multi-parameter medical inferences, flexible global scaling network delivery of status and alerts to caregivers, and feedback loop learning from physician instructions and caregiver observations concerning the status of the patient. Wearable monitors are microprocessor-based.
Azano Pharmaceuticals, Inc.
Azano will develop a proprietary C-reactive protein (CRP) product (Az-121) to treat patients with severe lupus nephritis. The potential of CRP to treat human lupus nephritis is based upon peer reviewed results in mouse models where a single dose of CRP has been found to provide dramatic reversal of disease and increased survival. Product sales related to this first indication are expected to exceed $300M annually in the United States. We will also explore the potential of Az-121 to treat other manifestations of systemic lupus and other autoimmune disorders. Azano will be led by former senior management of MGI PHARMA.
Chemica Technologies, Inc
Chemica Technologies, Inc is an internationally-focused research and development company focusing on development of unique healthcare products. By combining our expertise in biochemistry, synthetic chemistry, coordination chemistry, and chemical engineering, Chemica creates innovative medical and pharmaceutical products within high-value markets that solve unmet medical needs and significantly improve the quality of life for patients world-wide while providing lower cost and convenience to their care providers. Our current product pipeline includes a Dialysis Regeneration Cartridge (DRC) for home and portable hemodialysis and Novel Radioimaging Agents (NRIA) to selectively promote the uptake of radiometals by tumor cells.
Louisville Bioscience Inc.
Louisville Bioscience, Inc.'s (LBI) strategic focus is on early stage cancer detection which can dramatically improve patient survival rates and reduce healthcare costs. Our diagnostic platform is based on a scientific breakthrough in Differential Scanning Calorimetry of blood plasma. With a single drop of blood, this amazingly sensitive assay indicates the presence (or absence) of many different disease states including a variety of cancers (cervical, lung, ovarian, multiple myeloma). Healthy individuals display a signature Plasma Thermogram that is distinct from individuals with disease. This is a multi-billion dollar market opportunity due to the multiplicity of applications. The Company's first product will be a diagnostic test for cervical cancer, killer of 250,000 women annually. The Pap smear is the only current diagnostic with $2.5 billion in sales. The LBI management team has esteemed inventors Drs. Jonathan Chaires, James Graham Brown Chair in Cancer Biophysics and Bennett Jenson, inventor of the Merck blockbuster HPV vaccine Gardasil. A broad patent application has been filed for diagnostic analysis, target discovery and therapeutic monitoring. LBI is raising a $6 million private round of financing.
LUTS Technologies, Inc.
LUTS Technologies has developed minimally invasive, disposable devices utilizing low-frequency vibration for the treatment of cellular proliferation disorders. With an initial focus on Benign Prostatic Hyperplasia (BPH), LUTS Technologies is anticipating initial clinical studies for the BPH device, pending funding.
Parsortix, Inc
The core technology is a device that allows the separation of particles from a fluid, and their sorting by size. In principle this can be applied to any fluid in which particles are suspended, including blood and other biological fluids. The current status is that viability for separating cells from peripheral blood, by size, has been demonstrated, and work is underway to demonstrate the collection of fetal cells from peripheral maternal blood.
Spring Medical Systems
Spring Medical Systems, Inc. was founded in 1997 by a team of physicians and technology professionals to develop software solutions that empower physicians to manage the clinical and administrative aspects of their practices better while maintaining proven procedures and workflows. The Company has experienced record growth in revenues, partnerships, and customers due to strong demand for its SpringCharts® EHR electronic health record solutions and complementary products. Customers are located in 47 states and 6 foreign countries. Sales were up 75% in 2007. We are currently seeking $5 million in Series A funding for marketing, development and acquisitions.
TheraKine Ltd.
TheraKine is developing revolutionary biologic drug delivery technology. The first applications are ophthalmic: 28 million Americans with inflammatory, diabetic, or degenerative eye disease are still at risk of blindness because of inadequate therapies. The “Blood-Eye” barrier means existing biologics work poorly. Therakine will place these drugs inside the blood eye barrier, where disease occurs, with sustained release. Status: topical formulation for corneal injury and LASIK is in animal dose trials. Implant system demonstrated in-vitro, entering animal trials summer 2008. Targets include wet and dry AMD, DRP, uveitis, DME, and related diseases.
Life cycle extension for existing biologics adds extra value.
Xylos Corporation
Xylos is a medical device company that offers superior biomaterial solutions for the treatment, repair and replacement of human tissue. Our proprietary biocellulose technology possesses the effectiveness, versatility and safety profile to address a broad range of medical applications for surgical implantation and drug delivery. Unlike competitive materials harvested from humans and animals or developed from synthetic sources, our biomaterial can be engineered to meet precise product performance requirements. We have FDA-cleared products, completed M&A transactions for select, discrete business units with market leaders, and are advancing a musculoskeletal product pipeline targeting a U.S. market opportunity of $1 billion.
